The Genetic Polymorphisms of CYP2C9 and VKORC1 in the Saudi Population and Their Impact on Anticoagulant Management. [PDF]
Al Hamad M.
europepmc +1 more source
Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications. [PDF]
Yu J +4 more
europepmc +1 more source
Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases. [PDF]
Lee H, Kwon YJ, Chun YJ.
europepmc +1 more source
Genotipizacija CYP2C9 u kliničkoj praksi
CYP2C9 jedan je od najvažnijih i najobilnije eksprimiranih enzima sustava citokrom P450 (CYP) u ljudskim jetrima. Odgovoran je za biotransformaciju oko 15 % klinički važnih lijekova, uključujući kumarinske antikoagulante (varfarin), antikonvulzive (fenitoin, valproična kiselina), oralne antidijabetike (gliklazid, tolbutamid), blokatore angiotenzinskih ...
openaire +1 more source
<i>CYP2C9</i> polymorphism is associated with susceptibility to ischemic stroke in a Chinese population. [PDF]
Zhang J +5 more
europepmc +1 more source
Protein Levels of 16 Cytochrome P450s and 2 Carboxyl Esterases Using Absolute Quantitative Proteomics: CYP2C9 and CYP3A4 Are the Most Abundant Isoforms in Human Liver and Intestine, Respectively. [PDF]
Grangeon A +5 more
europepmc +1 more source

